VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CHE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CHEChemed Corporation
$546.72$7.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCHEBalance Sheet

Chemed Corporation (CHE) Balance Sheet

30Y historyFree accessUpdated daily

Total debt has climbed 179% from $140.8M in Q4 2024 to $392.2M in Q3 2026 while cash has fallen over 80% to $48.4M, pushing the current ratio down from 1.86 to 1.11 and raising the D/E ratio from 0.12 to 0.46.

Income StatementBalance SheetCash FlowRatios

CHE Balance Sheet

Annual statement

CHE Balance Sheet

Chemed Corporation (CHE) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets365.73M302.62M394.75M500.84M272.61M230.29M329.4M190.67M159.84M176.05M169.9M150.81M174.56M224.66M197.67M150.75M196.8M198.26M136.26M139.41M162.11M204.25M197.62M102.08M96.23M100.05M106.47M111.8M124.6M177.5M192.4M
Cash & Short-Term Investments48.43M74.52M178.35M263.96M74.13M32.9M162.68M6.16M4.83M11.12M15.31M14.73M14.13M84.42M69.53M38.08M49.92M112.42M3.63M4.99M29.27M57.13M71.45M50.59M37.73M9.01M10.28M17.3M41.4M71M11.9M
Cash Only48.43M74.52M178.35M263.96M74.13M32.9M162.68M6.16M4.83M11.12M15.31M14.73M14.13M84.42M69.53M38.08M49.92M112.42M3.63M4.99M29.27M57.13M71.45M50.59M37.73M9.01M10.28M17.3M41.4M71M11.9M
Short-Term Investments0000000000000000000000000000000
Accounts Receivable254.86M182.57M171.16M181.51M139.41M137.22M126.85M143.83M119.5M113.65M132.02M106.26M124.61M91.77M93.33M77.92M113M53.46M98.08M103.11M93.09M91.09M64.66M14.35M14.64M15.13M54.57M55.9M45.3M42.1M31.6M
Days Sales Outstanding28.8626.3425.729.2623.8323.4122.2627.0824.4724.8930.5625.1331.2323.723.8220.9832.2116.3931.1634.2133.3636.332.1220.0921.0716.3456.0644.9843.3644.9738.29
Inventory7.75M7.54M8.19M12M10.27M10.11M7.09M7.46M5.71M5.33M5.75M6.31M6.17M6.7M7.06M8.67M7.73M7.54M7.57M6.6M6.58M6.5M7.02M8.26M9.49M10.42M10.5M9.8M9.8M8.7M52.4M
Days Inventory Outstanding1.511.551.92.992.742.691.882.061.71.691.882.122.182.432.493.263.113.33.413.143.293.685.0620.5224.5818.518.3413.2615.5215.41107.21
Other Current Assets16.35M0000000000018.2M23.95M13.66M12.54M15.1M13.7M15.39M14.21M23.21M31.92M44.65M24.01M22.22M57.98M31.12M28.8M28.1M55.7M50.5M
Total Non-Current Assets1.35B1.34B1.27B1.17B1.17B1.11B1.11B1.08B815.69M743.98M710.16M701.52M685.37M669.04M661.96M645.15M633.36M621.21M624.66M632.91M631.17M630.84M627.95M226.98M242.7M296.46M314.9M309.5M305.1M271.3M367M
Property, Plant & Equipment360.99M336.81M328.16M330.23M335.38M318.73M311.27M287.42M162.03M143.03M121.3M117.37M105.34M92.95M91.93M82.95M79.29M75.36M76.96M74.51M70.14M65.45M55.8M41M48.36M67.59M75.18M71.7M61.7M53.1M83.3M
Fixed Asset Turnover10.93x7.51x7.41x6.86x6.37x6.71x6.68x6.74x11.00x11.65x13.00x13.15x13.83x15.20x15.56x16.35x16.15x15.79x14.93x14.76x14.52x14.00x13.17x6.36x5.25x5.00x4.73x6.33x6.18x6.44x3.62x
Goodwill754.76M667M666.74M585.02M581.29M578.59M578.59M577.37M510.57M476.89M472.37M472.32M466.72M466.87M465.83M460.63M458.34M450.04M448.72M438.69M435.05M0000161.07M00000
Intangible Assets78.79M82.76M92.21M90.26M99.73M108.1M118.08M126.37M68.25M54.87M55.06M55.11M56.03M56.56M57.18M58.26M56.41M57.92M61.3M65.18M69.22M509.11M509.66M105.93M113.73M4.04M180.72M175.9M168.9M156.6M204.2M
Long-Term Investments577.12M140.35M00098.88M88.81M77.45M65.62M62.07M54.39M49.48M49.15M42.47M36.09M31.63M28.3M24.16M22.63M29.42M00000000000
Other Non-Current Assets13.33M8.65M186.72M161.74M153M8.14M8.76M9.05M9.21M7.13M7.04M7.23M8.14M10.2M10.92M11.68M11.02M13.73M14.07M25.11M56.77M63.9M62.49M89.62M82.04M109.82M59.01M61.9M74.5M61.6M218.7M
Total Assets1.72B1.64B1.67B1.67B1.44B1.34B1.43B1.27B975.53M920.03M880.06M852.33M859.93M893.7M859.63M795.9M830.16M819.47M760.92M772.31M793.29M835.09M825.57M329.07M338.93M396.51M421.38M421.3M429.7M448.8M559.4M
Asset Turnover1.64x1.54x1.46x1.36x1.48x1.59x1.45x1.53x1.83x1.81x1.79x1.81x1.69x1.58x1.66x1.70x1.54x1.45x1.51x1.42x1.28x1.10x0.89x0.79x0.75x0.85x0.84x1.08x0.89x0.76x0.54x
Asset Growth %-14.97%-1.71%0.03%15.68%7.39%-6.42%13.13%30.01%6.03%4.54%3.25%-0.88%-3.78%3.96%8.01%-4.13%1.3%7.69%-1.47%-2.64%-5.01%1.15%150.88%-2.91%-14.52%-5.9%0.02%-1.95%-4.26%-19.77%5.17%
Total Current Liabilities330.93M287.13M285.69M312.05M297.2M302.4M299.11M262.22M191.67M193.52M171.83M171.34M175.55M363.99M156.82M145.4M149.34M136.08M154.05M152.83M166.06M168.9M169.18M59.09M69.87M85.11M106.94M98.4M91.1M94.4M124.5M
Accounts Payable65.3M53.46M44.15M64.03M41.88M73.02M54.23M51.1M50.15M48.37M39.59M43.7M46.85M41.76M48.47M48.23M55.83M52.07M52.81M46.17M49.74M43.44M37.78M6.08M5.69M9.13M11.1M11.2M10.3M8.8M9M
Days Payables Outstanding11.7811.0110.2215.9511.1619.4614.3614.1214.9115.3512.9514.6616.5315.1117.1218.1422.4922.7723.7821.9724.8724.627.2115.1214.7216.219.3915.1516.3115.5918.41
Short-Term Debt051.89M015.7M5M000010M8.75M7.5M6.25M183.56M000010.17M10.16M209K1.04M12.19M193K409K353K14.38M11.7M4.4M5.3M17.5M
Deferred Revenue (Current)0000000000000000000000014.36M17.32M22.19M24.97M0000
Other Current Liabilities58.34M120.95M134.75M121.87M145.84M134.63M133.88M114.44M93.57M86.4M73.73M74.94M75.07M73.48M61.6M59.94M16.14M14.13M12.18M13.93M41.66M53.35M75.84M32.47M23.88M58.02M56.49M75.5M76.4M80.3M63.9M
Current Ratio1.11x1.05x1.38x1.61x0.92x0.76x1.10x0.73x0.83x0.91x0.99x0.88x0.99x0.62x1.26x1.04x1.32x1.46x0.88x0.91x0.98x1.21x1.17x1.73x1.38x1.18x1.00x1.14x1.37x1.88x1.55x
Quick Ratio1.08x1.03x1.35x1.57x0.88x0.73x1.08x0.70x0.80x0.88x0.96x0.84x0.96x0.60x1.22x0.98x1.27x1.40x0.84x0.87x0.94x1.17x1.13x1.59x1.24x1.05x0.90x1.04x1.26x1.79x1.12x
Cash Conversion Cycle18.5916.8817.3716.315.416.649.7815.0211.2511.2419.4912.5916.8811.029.196.112.83-3.0810.7815.3811.7815.389.9625.4930.9318.6455.0143.0942.5744.79127.09
Total Non-Current Liabilities526.08M373.48M263.89M248.17M346.09M417.05M234.6M279.49M192.53M186.15M184.13M167.74M233.02M80.83M249.51M236.82M218.77M206.22M208.72M255.13M205.86M285.72M324.29M67.07M74.98M104.89M86.03M110.9M115.2M126.3M201.1M
Long-Term Debt236M00092.5M185M090M89.2M91.2M100M83.75M141.25M0174.89M166.78M159.21M152.13M199.66M214.67M150.33M234.06M279.51M25.93M25.6M61.04M58.39M78.6M80.4M83.7M158.2M
Capital Lease Obligations435.82M102.87M98.54M100.78M110.51M100.63M99.21M86.66M0-61.8M-54.29M00000000000000000000
Deferred Tax Liabilities169.62M121.14M25.95M30.32M38.61M23.18M20.66M18.5M21.6M16.64M14.29M21.04M29.95M27.3M27.66M29.46M25.09M25.92M7.6M5.8M26.3M22.3M16.81M00000006.7M
Other Non-Current Liabilities156.24M13.34M139.4M117.07M104.47M108.24M114.73M84.33M81.73M78.31M69.84M62.95M61.83M53.52M46.96M40.57M34.48M28.17M28.03M34.66M29.23M25.65M27.97M41.14M49.37M43.85M27.64M32.3M34.8M42.6M40M
Total Liabilities857.02M660.61M549.58M560.22M643.3M719.45M533.71M541.71M384.19M379.67M355.96M339.07M408.58M444.81M406.33M382.22M368.11M342.31M389.33M407.96M371.93M450.91M493.47M136.38M135.65M173.99M192.97M209.3M206.3M220.7M330.7M
Total Debt392.19M154.76M140.84M155.11M247.01M323.54M135.41M215.94M89.2M101.2M108.75M91.25M147.5M183.56M174.89M166.78M159.21M152.13M209.82M224.83M150.54M235.1M291.69M26.38M26.01M61.39M72.77M90.3M84.8M89M175.8M
Net Debt343.77M80.24M-37.51M-108.85M172.88M290.65M-27.27M209.78M84.37M90.08M93.44M76.52M133.37M99.15M105.36M128.7M109.29M39.71M206.2M219.84M121.27M177.97M220.25M-24.21M-11.72M52.38M62.49M73M43.4M18M163.9M
Debt / Equity0.46x0.16x0.13x0.14x0.31x0.52x0.15x0.30x0.15x0.19x0.21x0.18x0.33x0.41x0.39x0.40x0.34x0.32x0.56x0.62x0.36x0.61x0.88x0.14x0.13x0.28x0.32x0.43x0.38x0.39x0.77x
Debt / EBITDA0.89x0.38x0.33x0.39x0.61x0.80x0.30x0.71x0.32x0.68x0.51x0.42x0.74x1.13x0.94x0.91x0.92x0.99x1.31x1.52x1.17x2.30x3.73x12.56x2.88x1.53x1.28x1.93x2.27x2.56x4.08x
Net Debt / EBITDA0.78x0.20x-0.09x-0.27x0.43x0.72x-0.06x0.69x0.30x0.61x0.44x0.35x0.67x0.61x0.56x0.70x0.63x0.26x1.29x1.48x0.94x1.74x2.81x-11.52x-1.30x1.31x1.10x1.56x1.16x0.52x3.80x
Interest Coverage76.96x204.30x225.42x113.73x72.92x188.53x169.15x58.69x49.02x28.37x48.66x50.42x20.81x9.24x10.90x11.12x12.19x11.40x21.31x10.06x-----------
Total Equity861.42M979.4M1.12B1.11B798.72M623.27M901.2M726.61M591.33M540.35M524.1M513.25M451.36M448.89M453.29M413.68M462.05M477.16M371.59M364.35M421.36M384.18M332.09M192.69M203.28M222.52M228.41M212M223.4M228.1M228.7M
Equity Growth %-91.41%-12.47%1%38.71%28.15%-30.84%24.03%22.88%9.43%3.1%2.11%13.71%0.55%-0.97%9.57%-10.47%-3.17%28.41%1.99%-13.53%9.68%15.68%72.34%-5.21%-8.65%-2.58%7.74%-5.1%-2.06%-0.26%-8.41%
Book Value per Share65.5868.0273.6972.8952.9039.1154.9643.9635.1932.2831.2229.4625.3024.1523.4419.7520.0620.9815.9014.5315.8014.6113.489.6810.2811.4511.5010.0811.0611.3911.54
Total Shareholders' Equity861.42M979.4M1.12B1.11B798.72M623.27M901.2M726.61M591.33M540.35M524.1M513.25M451.36M448.89M453.29M413.68M462.05M477.16M371.59M364.35M421.36M384.18M332.09M192.69M203.28M222.52M228.41M212M223.4M228.1M217.9M
Common Stock37.76M37.59M37.42M37.18M36.8M36.51M36.26M35.81M35.31M34.73M34.27M33.98M33.34M32.24M31.59M30.94M30.38M29.89M29.52M29.26M28.85M28.37M13.49M13.45M13.45M13.44M13.32M13.7M000
Retained Earnings3.14B2.96B2.72B2.45B2.2B1.97B1.72B1.43B1.23B1.04B958.15M865.85M771.18M686.11M623.03M546.76M473.32M403.37M343.81M278.34M215.52M171.19M141.54M119.75M132.79M139.16M153.91M144.3M147M148.7M139.3M
Treasury Stock-4.01B-3.61B-3.13B-2.72B-2.59B-2.43B-1.82B-1.6B-1.45B-1.23B-1.11B-991.98M-894.28M-752.63M-640.73M-564.09M-408.62M-293.94M-285.98M-213.04M-78.06M-52.13M-33.87M-109.43M-111.58M-110.42M-105.25M-99.4M000
Accumulated OCI02.35M00002.34M2.31M2.34M2.2M2.51M2.4M2.28M2.15M2.04M1.99M0002.48M2.42M1.83M-1.76M-1.58M319K-1.44M-10.83M-11.1M000
Minority Interest00000000000000000000000000000010.8M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Debt-funded buybacks eroding cushion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Cash Position Inverts to Rising Leverage

Chemed's balance sheet has undergone a material transformation, with total debt rising 179% from $140.8M in Q4 2024 to $392.2M in Q3 2026 while cash fell from $178.3M to $48.4M, inverting the historically net-cash posture into a net-debt position. According to quarterly SEC filings.

This structural shift coincides with the cash flow finding that buybacks of approximately $1.18B over ten quarters have exceeded cumulative operating cash flow of $950.7M, suggesting management has drawn on debt to sustain its repurchase program. Total equity declined from $1.2B to $861.4M despite retained earnings growing by $500M, confirming that buyback-driven treasury stock accumulation is eroding the equity cushion. The D/E ratio's ascent from 0.12 to 0.46 remains moderate in absolute terms, but the trajectory warrants close monitoring if cash generation continues to weaken as the free cash flow margin compresses.

Leverage Ramp Tracks Buyback Funding Gap

Based on Chemed's reported balance sheets, total debt has more than doubled since Q1 2026 — rising from $236.9M to $392.2M in just two quarters — with the D/E ratio climbing from 0.28 to 0.46, representing the steepest quarterly borrowing pace in the ten-quarter window.

The acceleration in borrowing from a relatively stable $140–150M range through Q3 2025 to $392.2M appears consistent with the capital deployment pattern identified in the cash flow analysis, where buybacks have outpaced operating cash generation by roughly $230M. While a D/E of 0.46 remains well below the Ensign Group (ENSG) peer at 1.86 and even Addus (ADUS) at 0.19 is closer in absolute terms, the velocity of leverage expansion — not the absolute level — is the concern. Investors should assess whether this borrowing is transitional to support a temporary buyback acceleration or reflects a structural shift in capital allocation philosophy, as the latter would materially change the risk profile.

Cash Runway Narrows as Buffer Depletes

As reported in Chemed's quarterly filings, the current ratio has deteriorated from 1.86 in Q2 2025 to 1.11 in Q3 2026, while cash reserves have fallen from $249.9M to $48.4M — a decline of over 80% — leaving the thinnest liquidity cushion in the ten-quarter observation period.

A current ratio of 1.11 remains above the 1.0 threshold but has compressed materially from historical norms of 1.4–1.9, suggesting limited room for further deterioration without approaching working capital stress. The simultaneous decline in cash and increase in debt indicates that liquidity has been deliberately deployed rather than eroded by operating losses, but the buffer against reimbursement timing delays or working capital swings — which the cash flow analysis showed can swing $110M quarter-to-quarter — is now meaningfully thinner. Given VITAS's exposure to government payment timing and audit-driven clawbacks, this compressed buffer warrants close monitoring in upcoming quarters.

Buybacks Erode Equity Despite Earnings Accretion

According to Chemed's financial statements, total equity has contracted from $1.2B to $861.4M over ten quarters even as retained earnings expanded from $2.6B to $3.1B, implying that approximately $540M in share repurchases and treasury stock activity has consumed the equity base faster than earnings replenish it.

This dynamic is the natural counterpart to the buyback program that has deployed $1.18B over ten quarters, exceeding $950.7M in cumulative operating cash flow as previously noted in the cash flow analysis. The $500M increase in retained earnings signals genuine profitability, but the equity erosion confirms that capital return has been funded partly through balance sheet reserves and new borrowing rather than purely from organic cash generation. The practical effect is a smaller equity denominator amplifying ROE optics, which should be discounted when assessing genuine returns on invested capital.

Goodwill Creep and PPE Halving Under Scrutiny

Based on Chemed's reported figures, goodwill has expanded from $662.1M to $754.8M over the period — a $93M increase — while net PPE has collapsed from $334.5M to $144.0M, a 57% decline that raises questions about asset disposition, lease reclassification, or portfolio restructuring not yet reflected in headline results.

Goodwill now represents approximately 88% of total equity, meaning the reported book value is almost entirely comprised of acquisition-related intangible assets whose impairment risk is non-trivial given the regulatory headwinds facing VITAS. The simultaneous $190M decline in PPE is stark — it could indicate asset sales, a shift toward leasing, or a reclassification, but the balance sheet data alone does not confirm the driver and warrants investigation into the Q3 2025 to Q4 2025 transition where PPE dropped sharply. Given that goodwill has historically constituted over 45% of total assets, any impairment tied to hospice reimbursement deterioration would materially erode an equity cushion that already appears compressed by the aggressive buyback program.

CHE — Frequently Asked Questions

Quick answers to the most common questions about buying CHE stock.

What are the total assets of Chemed Corporation (CHE)?

As of 2025, Chemed Corporation (CHE) had total assets of $1.64B including $302.6M in current assets.

How much debt does Chemed Corporation (CHE) have?

Chemed Corporation (CHE) carries total debt of $154.8M, offset by $74.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Chemed Corporation?

Chemed Corporation (CHE) has total shareholders' equity (book value) of $979.4M ($68.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Chemed Corporation's current ratio and liquidity?

Chemed Corporation (CHE) reported a current ratio of 1.05x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.